Epix tests MRI blood clot agent in phase II trial :
This article was originally published in Clinica
Executive Summary
Epix Pharmaceuticals is starting a phase II proof-of-concept trial for its EP-2104R MRI-based agent for detecting blood clots throughout the body. The study's launch follows the completion late last year of a phase I trial that showed the agent to be well tolerated by healthy subjects at all doses tested. The phase II programme, which is expected to enrol around 40 patients, is being conducted at multiple clinical sites worldwide. Cambridge, Massachusetts-based Epix is collaborating on EP-2104R's development with German firm Schering.